THE introduction of a two-dose schedule of Shingrix (recombinant protein subunit) herpes zoster vaccine on the National Immunisation Program (NIP) in Nov 2023 has resulted in a 40% increase in vaccination in Australians aged 65 , according to the National Centre for Immunisation Research and Surveillance (NCIRS).
Shingrix (GSK), which was previously only available privately, replaced the single-dose Zostavax on the NIP, as it provides superior, longer-lasting protection and is safe for immunocompromised people.
Using Australian immunisation data to track the uptake of Shingrix in its first year, the researchers reported that over 2.52 million doses were administered to over 65s, of which around 1.48 million were initial doses and 1.04 million were second doses.
Shingles coverage increased from 31.3% among over 65s pre-Shingrix to 44.1% in late 2024, and in total, almost one-third (32%) of all NIP eligible adults received at least one dose.
Most Shingrix doses (83%) were administered in general practice.
While the findings were encouraging, the team noted that equity gaps in uptake exist in remote and socioeconomically disadvantaged areas, and despite high risk, less than half of adults aged 65 and older years have adequate shingles protection.
"Health services and vaccination providers can continue improving protection by promoting Shingrix vaccination among eligible adults through opportunistic vaccination, co-administration with other vaccines and targeted efforts to support equitable access," the team concluded. KB
The above article was sent to subscribers in Pharmacy Daily's issue from 15 Jan 26
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Jan 26
